EUVIMEDEUVIMED entdecken
Crossref

Effect of Renin-Angiotensin-Aldosterone System Blockers on Adverse Outcomes in COVID-19 Patients

Poornima Vinod, Vinod Krishnappa, William Rathell, Godwin Dogbey, Hiten Patel, William Herzog

Cardiology · 2024

DOI: 10.1159/000540499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiology, 2024. Verfasst von Poornima Vinod und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of North Carolina Health Southeastern, Lumberton, North Carolina, USA. Hauptthemen laut MEDLINE: COVID-19, Angiotensin-Converting Enzyme Inhibitors, Renin-Angiotensin System. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Angiotensin-converting enzyme 2 (ACE2) of the renin-angiotensin-aldosterone system (RAAS) serves as a functional receptor to gain entry into the cells for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). The interaction between SARS-CoV-2 and ACE2 is a potential virulent factor in infectivity. Our study aimed to ascertain the association of RAAS inhibitors with adverse cardiovascular and other outcomes in hospitalized COVID-19 patients.

Methods

This is a retrospective study of medical records of ≥18-year-old patients hospitalized for COVID-19 from March 2020 to October 2020. Primary outcomes were acute cardiovascular events (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction type 1, acute congestive heart failure, acute stroke) and mortality. Secondary outcomes were respiratory failure, need for and duration of mechanical ventilation, acute deep vein thrombosis or pulmonary embolism (DVT/PE), and readmission rate.

Results

Among 376 hospitalized COVID-19 patients, 149 were on RAAS inhibitors. No statistically significant differences were found between RAAS inhibitor and non-RAAS inhibitor groups with respect to acute cardiovascular events (6% vs. 6.2%, p = 0.94), acute DVT/PE (4.7% vs. 4.8%, p = 0.97), hypoxia (62.4% vs. 58.6%, p = 0.46), need for mechanical ventilation (18.1% vs. 16.7%, p = 0.72), mortality (19.5% vs. 22%, p = 0.56), and readmission rate (11.4% vs. 14.1%, p = 0.45). Some nuances discovered were a higher rate of hospitalizations among Native Americans receiving RAAS inhibitors (30.2% vs. 19.8%) and significantly lower levels of procalcitonin in patients on RAAS inhibitors.

Conclusions

Among hospitalized patients with COVID-19, those on RAAS inhibitors showed no significant differences in acute cardiovascular events, acute DVT/PE, hypoxia, need for mechanical ventilation, readmission, or mortality rate compared to those not on them. However, further large-scale studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Angiotensin-Converting Enzyme InhibitorsRenin-Angiotensin SystemHumansRetrospective StudiesFemaleMaleAgedMiddle AgedSARS-CoV-2Angiotensin Receptor AntagonistsCardiovascular DiseasesHospitalizationRespiration, Artificial

Stichwörter der Autor:innen

Acute cerebrovascular accidentsCoronavirus disease 2019Non-ST-elevation myocardial infarctionRenin-angiotensin-aldosterone system inhibitorsST-Elevation myocardial infarction

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, University of North Carolina Health Southeastern, Lumberton, North Carolina, USA.
  • Department of Research and Medical Education, Campbell University, Buies Creek, North Carolina, USA.
  • Department of Cardiology, University of North Carolina Health Southeastern, Lumberton, North Carolina, USA.
  • Department of Cardiology, Duke University, Durham, North Carolina, USA.

Zitieren

APA

Vinod, P., Krishnappa, V., Rathell, W., Dogbey, G., Patel, H., & Herzog, W. (2024). Effect of Renin-Angiotensin-Aldosterone System Blockers on Adverse Outcomes in COVID-19 Patients. Cardiology. https://doi.org/10.1159/000540499

Vancouver

Vinod P, Krishnappa V, Rathell W, Dogbey G, Patel H, Herzog W. Effect of Renin-Angiotensin-Aldosterone System Blockers on Adverse Outcomes in COVID-19 Patients. Cardiology. 2024. doi:10.1159/000540499

BibTeX
@article{Vinod2024,
  author = {Vinod, Poornima and Krishnappa, Vinod and Rathell, William and Dogbey, Godwin and Patel, Hiten and Herzog, William},
  title = {Effect of Renin-Angiotensin-Aldosterone System Blockers on Adverse Outcomes in COVID-19 Patients},
  journal = {Cardiology},
  year = {2024},
  doi = {10.1159/000540499}
}
Kostenlos starten →